Navigation Links
Sangamo BioSciences Reports Third Quarter 2009 Financial Results
Date:11/4/2009

lion to $10.0 million, up to a total of $25.0 million, based upon cumulative product sales.
  • Announcement of a second Phase 1 clinical trial of SB-728-T for the treatment of HIV/AIDS. In September 2009, Sangamo announced the successful review and acceptance by the FDA of an Investigational New Drug (IND) application to initiate an open-label, repeat-dosing Phase 1 clinical trial (SB-728-T-902) of the company's ZFP nuclease (ZFN)-based therapeutic, SB-728-T. A single dose Phase 1 clinical study of SB-728-T was initiated in February 2009 and is ongoing at the University of Pennsylvania. Both Phase 1 studies are designed primarily to evaluate the safety and tolerability of this ZFP Therapeutic approach. However, subjects' CD4 T-cell counts, levels of CCR5-modified T-cells and viral burden will also be monitored.
  • Publication of ground-breaking new ZFN-mediated gene editing applications in stem cells. Scientists from The Whitehead Institute led by Dr. Rudolf Jaenisch used ZFNs designed by Sangamo to efficiently and precisely modify the genomes of human embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs). Human ESCs and iPSCs are useful tools in drug discovery and development. Scientists also hope to use these cells therapeutically in transplantation medicine and other regenerative applications. The research was described in a paper published in the scientific journal Nature Biotechnology (Nat Biotechnol. 2009 Sep; 27(9):851-7).
  • Sangamo's collaborators awarded significant clinical research awards to advance research into potential ZFP Therapeutics. Sangamo's collaborators at the City of Hope and University of Southern California were awarded a $14.5 million grant from the California Institute of Regenerative Medicine (CIRM). The grant will support the development of a ZFN-based stem cell therapy for HIV/AIDS. In addition, research led by Donald B. Kohn, M.D., Director of the UCLA Human Gene
    '/>"/>

    • SOURCE Sangamo BioSciences, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    1

    GOOD

    Page: 1 2 3 4 5 6 7 8

    Related medicine news :

    1. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
    2. Sangamo BioSciences Provides Update on Companys Accomplishments in 2007 and 2008 Objectives
    3. Sangamo BioSciences Reports First Quarter 2009 Financial Results
    4. Sangamo BioSciences Announces Presentation at the JMP Securities Research Conference
    5. Sangamo BioSciences Presents Positive Phase 2 ZFP Therapeutic Data at ADA 2009
    6. Sangamo BioSciences Announces Presentation of Top-Line Statistically Significant Phase 2 Data in Diabetic Neuropathy at Society for Neuroscience Meeting
    7. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
    8. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
    9. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
    10. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
    11. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/4/2009)SCOTTSDALE, Ariz., Dec. 4 Healthcare Trust of America, Inc. ("HTA"), a self-managed, non-traded, real estate investment trust, announced the execution of a purchase and sale agreement to acquire a th
    (Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud
    (Date:12/4/2009)WASHINGTON, Dec. 4 While Congress debates whether health care reform would control health care costs, Leapfrog,s purchaser members point to 45 hospitals that lead through example -- delivering the be
    (Date:12/4/2009)Late recurrence is a risk for some pediatric cancers, particularly Ewing sarcomas and tumors of the central nervous system, according to a new study published online December 4 in the Journal of the
    (Date:12/4/2009)Working with mice, scientists at Johns Hopkins publishing in the December issue of Neoplasia have shown that a protein made by a gene called "Twist" may be the proverbial red flag that can accuratel
    Breaking Medicine News(10 mins):Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire a 92,500 Square Foot Medical Office Portfolio Located in Texas and Indiana 2Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 3Health News:Potential new 'twist' in breast cancer detection 2Health News:Potential new 'twist' in breast cancer detection 3
    ...new genetic risk factors for rheumatoid arthritis ... risk factors identified so far have been associat...out two-thirds of RA patients, but distinguishing ... of Leiden University Medical Center in The Nether...
    ...search for Usability Evaluation of HIT Providers ,...eed for understanding the usability of Electronic ...tric.com ) launches the first syndicated user per...n now is usability. Up to now the focus for compar...
    ...k, but human application is unclear , , TU... put down that protein shake -- at least if you,re...n protein spell trouble for rats that already eat ... about protein in the development of diabetes, sai...
    ...pectation may be factors in helping older adults r...n, say researchers with the Birmingham Veterans Ad... Alabama at Birmingham). In findings published in ... and more completely than did patients hospitalize...
    ... Cross Blue Shield of Georgia (BCBSGa) announced t...t rate for clinical psychologists by approximately...your auto mechanic or home handyman per hour. , ...al psychologists were reimbursed by BCBSGa nearl...
    ... Vision Screenings , , SAN ANTONIO, April 7 Sa...Vision eye care professionals are teaming up with ...ter to provide free vision screenings for children...tion and a free pair of eyeglasses from participat...
    Other Medicine News:Health News:Genetic risk factors play role in autoantibody-negative rheumatoid arthritis 2Health News:EMRs Put to the Test on Usability 2Health News:EMRs Put to the Test on Usability 3Health News:Protein Might Be a Troublesome Nutrient 2Health News:VA/UAB study looks at functional decline in older patients after hospitalization 2Health News:VA/UAB study looks at functional decline in older patients after hospitalization 3Health News:Blue Cross Blue Shield of Georgia Is Skimping on Mental Health Care, Says Georgia Psychological Association 2Health News:Blue Cross Blue Shield of Georgia Is Skimping on Mental Health Care, Says Georgia Psychological Association 3Health News:Local EyeMasters Stores and Davis Vision to Team Up with San Antonio Spurs 2
    (Date:12/4/2009)SALT LAKE CITY, Dec. 4 Dynatronics Corporation (Nasdaq: DYNT ) announced it has signed a sole-source vendor agreement to provide therapy equipment and rehab supplies to Benchmark Physical Therapy wi
    (Date:12/4/2009)WASHINGTON, Dec. 4 Chemistry World recently highlighted a new report published by the Pharmaceutical Research and Manufacturers of America ( PhRMA ) that identifies 97 new drugs and vaccines in
    (Date:12/4/2009)ANNAPOLIS, Md., Dec. 4 PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the Company is prese
    Breaking Medicine Technology:U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 610 x 20 3A ID experts call for 10 new antibiotics by 2020 61960 110 x 20 3A ID experts call for 10 new antibiotics by 2020 61960 210 x 20 3A ID experts call for 10 new antibiotics by 2020 61960 3Switchgrass produces biomass efficiently 10873 1Switchgrass produces biomass efficiently 10873 2UNH prof receives nearly 24500 000 to research environmentally significant plants 10871 1UNH prof receives nearly 24500 000 to research environmentally significant plants 10871 2
    English & Spanish Medical Words & Phrases, 3rd Ed.
    PocketBilling©
    BluefishRx ICD-9 2005 Coding Tool
    MD Coder Pocket PC 2006
    Medicine Products: